Toronto, September 7, 2021 – MORSE Consulting is pleased to announce the addition of Katherine Scott as a Consultant.
The Canadian public system remains one of the critical payers in this country’s pharmaceutical reimbursement pathway. This system is growing increasingly complex with new funding mechanisms for emerging gene and cell therapies, novel approaches related to outcomes-based agreements, evolving policies related to biosimilars, and variations in how provincial payers implement pCPA negotiations. As a result, there is a pressing need for stakeholders to benefit from a better understanding of the latest developments from a public payer perspective.
With the addition of Katherine Scott, MORSE Consulting further strengthens its strategic advice capabilities related to the public payer market. Katherine has more than 3 years of experience working for two Canadian public payers where she built extensive knowledge regarding public drug plans as well as the interplay with the overall pharmaceutical landscape. Her roles in both New Brunswick and Alberta supported public payer decision making and she was an active participant in pan-Canadian Pharmaceutical Alliance (pCPA) operations. She has led and supported numerous pCPA negotiations and subsequent product listing agreement implementation in both provinces. She was integral to the development and implementation of multiple policy initiatives, including the Alberta Biosimilar Initiative. Katherine’s background in economics, along with her experience with two public drug plans and the pCPA provide a unique and valuable perspective when working towards market access solutions.
As a Consultant, Katherine supports MORSE’s clients by providing public payer and pCPA insights to inform the development of their overall reimbursement strategy, including pCPA assessments, advisory board participation and simulated pCPA negotiation services.